S 670

Speeding Therapy Access Today Act of 2021

Congress: 117 (2021–2023, Ended)
Chamber: Senate
Policy Area: Health
Introduced: Mar 10, 2021
Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Mar 10, 2021)
Official Text: https://www.congress.gov/bill/117th-congress/senate-bill/670

Sponsor

Name: Sen. Klobuchar, Amy [D-MN]
Party: Democratic • **State:** MN • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Wicker, Roger F. [R-MS]	R · MS		Mar 10, 2021

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Mar 10, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 1730	Identical bill	**Mar 10, 2021:** Referred to the Subcommittee on Health.

Summary (as of Mar 10, 2021)

Speeding Therapy Access Today Act of 2021

This bill requires and authorizes various actions to accelerate the development of therapies for rare diseases.

The Food and Drug Administration (FDA) shall establish the Intercenter Institute on Rare Diseases and Conditions. The institute shall (1) coordinate engagement with relevant stakeholders, (2) build the FDA's expertise in the review of medical products to treat rare diseases, (3) coordinate regulatory science initiatives related to rare diseases, (4) establish and implement a program to make recommendations to address challenges associated with developing medical products to treat rare diseases in an individual or in very small populations, (5) convene a stakeholder meeting to consider potential amendments to labels for medical products to treat rare diseases, and (6) establish and carry out a program to facilitate voluntary communication between the sponsors of such medical products and third-party payers (e.g., insurance companies).

The bill also authorizes the FDA to make grants to assist in developing practices related to the development and production of individualized therapies or therapies to treat very small populations.

The bill also establishes an advisory committee to advise the FDA on issues related to the development of therapies to treat rare diseases.

Actions Timeline

- **Mar 10, 2021:** Introduced in Senate
- **Mar 10, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.